Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
DNL343 demonstrated extensive blood-brain barrier penetration and robustly inhibited the integrated stress response pathway implicated in ALSOnce-daily oral dosing with DNL343 for 28 days was... | December 5, 2022
United States Seanm Healey Laura Hansen Denali Therapeutics Inc Exchange Commission Department Of Neurology
Source: marketscreener.com